Form 8-K - Current report:
SEC Accession No. 0000950170-24-121089
Filing Date
2024-11-05
Accepted
2024-11-05 08:31:35
Documents
13
Period of Report
2024-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20241105.htm   iXBRL 8-K 41392
2 EX-99.1 inzy-ex99_1.htm EX-99.1 148788
3 GRAPHIC img4202433_0.jpg GRAPHIC 8171
  Complete submission text file 0000950170-24-121089.txt   333152

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inzy-20241105.xsd EX-101.SCH 25818
15 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20241105_htm.xml XML 4880
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 241425879
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)